Global contract research organisation (CRO) Premier Research has appointed Martin Nicklasson, the former CEO of AstraZeneca Sweden, to its Board of Directors.
Nicklasson is a native of Sweden with international biopharmaceutical experience at executive and board level. In addition to his role at AstraZeneca, he served as CEO of Biovitrum before retiring to found Nicklasson Life Science. He currently chairs the Board of Directors of Basilea Pharmaceuticals, Orexo AB, and Farma Holdings AS, and is a non-executive director of Biocrine AB, Pozen Inc, and Oasmia AB.
Premier Research’s R&D work focuses on analgaesia, the central nervous system, rare diseases, medical devices and paediatric research.
Copyright - Unless otherwise stated all contents of this web site are © 2014 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
Subscribe to our FREE newsletter
Results from the 50 Most Influential People in Vaccines, Aligent changes CEOs, and more...
On the eve of the historical vote on Scottish independence from the UK tomorrow, we take a...
New execs for ICON and PPD, plus services shake-ups in this week's column.
Regulatory experts dominate this week's column on who's who in pharmaceutical outsourcing.